Real-World Evidence Study Backs Adalimumab for Childhood Uveitis

May 17, 2023

Newly published research in Ophthalmology and Therapy finds that adalimumab is effective and safe in the treatment of pediatric non-anterior uveitis, an inflammatory eye disease. The study, using real-world evidence (RWE) from 21 pediatric patients, found that all patients benefited from the therapy and half were deemed fully responsive, with no additional inflammation in the affected eyes.

According to Connor Iapoce, “Moreover, 10 cases (17 affected eyes) showed a significant clinical improvement, including reduced frequency and severity of ocular relapses in 4 patients; reduced frequency of ocular relapses in 3 patients; and reduced severity of ocular relapses in 3 patients. They were included in the group of “less responsive” patients, while no patients were unresponsive to treatment. Overall, the study recorded 94 relapses in the year prior to the start of adalimumab, corresponding to 3.91 ocular flares per patient year.”

To read more, click here.